Loretta Gammaitoni

Medicine · Health Sciences

30h-index3.3kcitations142works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CAR-T cell therapy research(64), Sarcoma Diagnosis and Treatment(34), Immune Cell Function and Interaction(26), Cancer Immunotherapy and Biomarkers(20), Hematopoietic Stem Cell Transplantation(19)

Publications142 total

Supplemental Figure 3 from Novel Lymphocyte-Independent Antitumor Activity by PD-1 Blocking Antibody against PD-1<sup>+</sup> Chemoresistant Lung Cancer Cells
2025Open Access
Supplemental Figure 2 from Novel Lymphocyte-Independent Antitumor Activity by PD-1 Blocking Antibody against PD-1<sup>+</sup> Chemoresistant Lung Cancer Cells
2025Open Access
Supplemental Figure 1 from Novel Lymphocyte-Independent Antitumor Activity by PD-1 Blocking Antibody against PD-1<sup>+</sup> Chemoresistant Lung Cancer Cells
2025Open Access
CSPG4 CAR-redirected Cytokine Induced Killer lymphocytes (CIK) as effective cellular immunotherapy for HLA class I defective melanoma
UNC Libraries·2025Open Access
CSPG4 CAR-redirected Cytokine Induced Killer lymphocytes (CIK) as effective cellular immunotherapy for HLA class I defective melanoma
Journal of Experimental & Clinical Cancer Research·2023· 8 citedOpen Access
Baseline Values of Circulating IL-6 and TGF-β Might Identify Patients with HNSCC Who Do Not Benefit from Nivolumab Treatment
Cancers·2023· 4 citedOpen Access
Inter-laboratory method validation of CD34+ flow-cytometry assay: the experience of Turin Metropolitan Transplant Centre.
PubMed·2023· 3 citedOpen Access
A joint profile of cytokines and immune cell populations may identify HNSCC patients who benefit from nivolumab treatment. The Gruppo Oncologico Nord-Ovest (GONO) study Nivactor T-2 
Research Square (Research Square)·2023Open Access
Supplemental Figure 1 from Novel Lymphocyte-Independent Antitumor Activity by PD-1 Blocking Antibody against PD-1<sup>+</sup> Chemoresistant Lung Cancer Cells
2023Open Access
Supplemental Figure 3 from Novel Lymphocyte-Independent Antitumor Activity by PD-1 Blocking Antibody against PD-1<sup>+</sup> Chemoresistant Lung Cancer Cells
2023· 1 citedOpen Access
Data from Novel Lymphocyte-Independent Antitumor Activity by PD-1 Blocking Antibody against PD-1<sup>+</sup> Chemoresistant Lung Cancer Cells
2023Open Access
Supplemental Figure 1 from Novel Lymphocyte-Independent Antitumor Activity by PD-1 Blocking Antibody against PD-1<sup>+</sup> Chemoresistant Lung Cancer Cells
2023Open Access
Supplemental Figure 3 from Novel Lymphocyte-Independent Antitumor Activity by PD-1 Blocking Antibody against PD-1<sup>+</sup> Chemoresistant Lung Cancer Cells
2023Open Access
Supplemental Figure 2 from Novel Lymphocyte-Independent Antitumor Activity by PD-1 Blocking Antibody against PD-1<sup>+</sup> Chemoresistant Lung Cancer Cells
2023Open Access
Supplemental Figure 2 from Novel Lymphocyte-Independent Antitumor Activity by PD-1 Blocking Antibody against PD-1<sup>+</sup> Chemoresistant Lung Cancer Cells
2023Open Access
Data from Novel Lymphocyte-Independent Antitumor Activity by PD-1 Blocking Antibody against PD-1<sup>+</sup> Chemoresistant Lung Cancer Cells
2023Open Access
Supplementary Data from CSPG4-Specific CAR.CIK Lymphocytes as a Novel Therapy for the Treatment of Multiple Soft-Tissue Sarcoma Histotypes
2023Open Access
Supplemental Figure 2 from CSPG4-Specific CAR.CIK Lymphocytes as a Novel Therapy for the Treatment of Multiple Soft-Tissue Sarcoma Histotypes
2023Open Access
Suppl. Video 4 from CSPG4-Specific CAR.CIK Lymphocytes as a Novel Therapy for the Treatment of Multiple Soft-Tissue Sarcoma Histotypes
2023Open Access
Supplemental Figure 5 from CSPG4-Specific CAR.CIK Lymphocytes as a Novel Therapy for the Treatment of Multiple Soft-Tissue Sarcoma Histotypes
2023Open Access
page 1 of 8Next →

Frequent Co-authors

Massimo Aglietta(44), Dario Sangiolo(25), Wanda Piacibello(18), Franca Fagioli(17), Giovanni Grignani(16), Valeria Leuci(15), Ymera Pignochino(13), Lidia Giraudo(13), Giuliana Cavalloni(12), Giulia Mesiano(12), F Sanavio(10), Fabrizio Carnevale‐Schianca(10), Ramona Rotolo(10), Stefania Bruno(9), Marco Basiricò(8), Lorenzo D’Ambrosio(8), Monica Gunetti(8), Maja Todorovic(7), Alberto Pisacane(6), Alessandra Danè(5)